Rede D'Or jumps 6% on Ibovespa with strong Q2 2026 Ebitda margin

However, our portal's recent editorial collection reveals extreme volatility and a predominantly challenging sentiment for the Equities category, this being the fifth major sector news of the week, contrasting sharply with the pessimism seen in competitor balance sheets and Hapvida's recent 20% drop following frustrating profits of R$ 12 million. To decipher this movement, the analytical school of Credit and Liquidity Cycles teaches us that, in moments of monetary tightening with the Selic rate strictly maintained at 14.00% per year, highly leveraged companies struggle to roll over debts, but those that generate their own cash — like Rede D'Or — manage to shield their operations, attracting institutional capital flows even with high benchmark interest rates.

Deepening the technical analysis of RDOR3's balance sheet, the advance in the Ebitda margin eliminates recent fears brought by the supplemental health market, which had been suffering from high loss ratios and the breakdown of corporate math in passing on drug and procedure price hikes. The 6% stock surge is not just a reflection of momentary optimism, but a fundamentalist repricing justified by efficiency in capital allocation and strict control of net debt. In practical terms, companies that maintain resilient operating margins in a scenario of a Selic rate at 14.00% per year demonstrate sectoral monopoly power and undeniable pricing power without expressive loss of client base.

Looking to the short and medium-term horizons, we project for the next 30 days a consolidation of RDOR3's share price in the technical support range conquered after the earnings report, with a high probability of maintaining foreign and institutional interest. In the 90-day horizon, the stabilization of the dollar around R$ 5.16 and controlled inflation at 4.44% over 12 months should continue to favor the high-complexity healthcare sector, reducing volatility and raising the predictability of quarterly profits.